Results (SD) before and after SGLT2 inhibitors treatment were: HbA1c. 8, 48 (1, 1) vs. 7, 44
(0.8)%(p< 0, 01);(37% achieved HbA1c< 7%) Weight: 91, 0 (18) vs. 88, 8 (17) kg (p< 0, 01); …

The aim of this study was to investigate the effectiveness of SGLT2 inhibitors with regard to
metabolic parameters and patient safety under routine ambulatory conditions. Retrospective …

Sodium-glucose cotransporter 2 (SGLT2) inhibitors were developed to control blood glucose
levels in patients with type 2 diabetes. However, their ability to reduce cardiovascular …

SGLT2 inhibitors have been shown to have benefits on glycaemic control, as well as on
cardiovascular risk factors including weight loss, blood pressure reduction and some effects …

Introduction: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are the newest class of
oral antihyperglycemic medications approved for the treatment of type 2 diabetes mellitus …

Background: Glycaemic control in type 2 diabetes mellitus can be difficult to attain, even with
a combination of multiple oral agents as well as Insulin. SGLT2 inhibitors are potential novel …

SGLT2 inhibitors: practical considerations and recommendatio... : Current Opinion in
Cardiology SGLT2 inhibitors: practical considerations and recommendations for …

Abstract# 284 Objective: Diabetes mellitus type 2 [DM 2] and essential hypertensive disease
[EHD] are interrelated diseases requiring the search for effective treatment. This research …

Background According to statistical data of the International Diabetes Federation in 2015 the
number of diabetes mellitus (DM) patients was 415 millions. By 2040, projected number of …

SGLT2 inhibitors are very modest in their efficacy in terms of lowering glycemia while
incurring undue cost burden to the patients, thus with very low cost efficacy. Moreover, the …